As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

Neurologists hope this tongue-in-cheek study will spark serious conversations about AI's limitations and the benefits of a human touch in medicine.

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

The average life expectancy of people diagnosed with dementia ranges from 9 years at age 60 to 4.5 years at age 85 for women ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

Higher green tea consumption significantly reduces cerebral white matter lesions in older adults, offering potential ...

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.

Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody ...